| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.007 | 0.9 |